ArticleBMC complementary medicine and therapies2025
Comprehensive Network pharmacology and in vitro investigation of L-mimosine: unveiling multi-targeted therapeutic potential against breast cancer.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains the leading cause of mortality among women globally, primarily due to its heterogeneity and complex pathophysiology. Conventional treatments such as surgery, radiation therapy, and chemotherapy often face limitations, including significant side effects and the development of drug resistance. Consequently, there is an urgent need to identify novel, effective natural compounds with anti-tumor properties. L-mimosine, a non-protein amino acid derived from the seeds of Leucaena leucocephala and Mimosa pudica, has demonstrated cytotoxic activity against various cancers, including sarcoma, melanoma, breast cancer, and lung cancer. However, its precise molecular mechanisms remain poorly understood. To elucidate these mechanisms, a network pharmacology approach was employed, complemented by molecular docking, molecular dynamics simulations, and in vitro experiments to evaluate the impact of L-mimosine on breast cancer cell proliferation. Breast cancer-associated targets and L-mimosine-interacting genes were retrieved from multiple databases. Pharmacokinetic and toxicity properties were assessed through ADMET analysis. Protein-protein interaction networks of overlapping genes were constructed, identifying key hub genes such as SRC, MAPK8, PRKACA, and AKT1. Among these, AKT1 demonstrated the highest docking scores in molecular docking studies, and molecular simulations confirmed the stability of L-mimosine binding to AKT1. In vitro assays validated that L-mimosine inhibits breast cancer cell proliferation by inducing DNA damage and apoptosis in a dose-dependent manner. Furthermore, L-mimosine was found to arrest MCF-7 cells in the S phase of the cell cycle, as analyzed through cell cycle assays. This research highlights L-mimosine's potential as a promising anticancer agent against breast cancer by promoting apoptosis and interfering with cancer cell cycle progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.